-+ 0.00%
-+ 0.00%
-+ 0.00%

ArriVent Biopharma Presents Phase 1 Data for ARR-217 in Advanced Solid Tumors

PUBT·11/09/2026 22:11:05
ArriVent Biopharma Presents Phase 1 Data for ARR-217 in Advanced Solid Tumors
  • ArriVent Biopharma continues enrolling its pivotal global Phase 3 firmonertinib trial for first-line EGFR PACC-mutated non-small cell lung cancer.
  • The 480-patient trial compares firmonertinib 240 mg daily with investigators' choice of osimertinib or afatinib.
  • Earlier first-line PACC data showed a 68.2% confirmed response rate at 240 mg, with median progression-free survival of 16 months.
  • ARR-217 remains in Phase 1b colorectal cancer dose optimization; preliminary results at 6 mg/kg showed a 44.8% response rate among 29 patients.
  • Grade 3 or higher treatment-related adverse events occurred in 20.4% at 6 mg/kg; no patients at that dose discontinued treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.